Latest Lamotrigine Stories
WALTHAM, Mass., Aug.
SILVER SPRING, Md., Aug. 12 /PRNewswire-USNewswire/ -- The U.S.
While the Food and Drug Administration (FDA) requires a warning of an increased risk of suicide for all epilepsy drugs, a new study shows that only certain drugs may increase the risk.
ATLANTA, June 29 /PRNewswire/ -- New long term data showed that VimpatÂ® (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures in adults with epilepsy.
Researchers have found that polytherapy with multiple anti-epileptic drugs (AEDs) did not result in greater adverse effects than monotherapy for patients with refractory epilepsy.
OHSU Doernbecher Children's Hospital is part of largest-ever NIH-funded pediatric epilepsy clinical trial to examine which of 3 standard treatments is most effective.
ATLANTA, March 11 /PRNewswire/ -- UCB today announced that the antiepileptic drug (AED) VimpatÂ® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia. This study was one of three that supported the approval of Vimpat by the U.S.
The first comprehensive comparative effectiveness clinical trial of three widely used anti-seizure drugs for childhood absence epilepsy â€“ the most common form of epilepsy in kids â€“ has established an evidence-based approach for initial drug therapy.
RESEARCH TRIANGLE PARK, N.C., Jan. 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S.
RESEARCH TRIANGLE PARK, N.C., June 1 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S.
- A hairdresser.